SENSEX NIFTY
May 15, 2009, 06.32 PM IST | Source: CNBC-TV18

Dr Reddys Labs Q4 PAT seen up 32% at Rs 137 cr

Dr Reddys Laboratories is to announce its fourth quarter FY09 results. According to CNBC-TV18 estimates, its consolidated, US GAAP (But Q4 nos will IFRS will be IFRS and not US GAAP) .

Dr Reddys Labs Q4 PAT seen up 32% at Rs 137 cr

Dr Reddys Laboratories is to announce its fourth quarter FY09 results.  According to CNBC-TV18 estimates, its consolidated, US GAAP (But Q4 nos will IFRS will be IFRS and not US GAAP) .

Its net sales is seen up 24% at Rs 1640 crore versus Rs1325 crore.

Its operating profit is seen up at Rs 225 crore versus Rs 172.5 crore.

Its OPM is seen at 14% versus 13%.

Its net profit is expected to go up 32% at Rs 137 crore versus Rs 102.8 crore.

Key factors to watch for:

Write offs from Betapharm expected in the range of Rs  200- 250 crore (not included in the estimates Final PAT figure may actually  be loss because  of this ) related to intangible impairment in Germany

Betapharm acquisition.

-Generic  Imitrex to contribute about Rs 150 Cr to the top line and Rs 40-50 crore  to the net profits

READ MORE ON  Dr Reddys Laboratories
Set email alert for

ADS BY GOOGLE

video of the day

India inflation to drop at startling levels in 2015: Walker

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.